Lebrikizumab is an effective treatment for moderate-to-severe atopic dermatitis in patients ≥60 years of age

Category Systematic review
JournalBr. J. Dermatol.
Year 2024
This article has no abstract
Epistemonikos ID: 5ad81e7fa5722b2079889cf026a9d51a2f716aaf
First added on: Sep 04, 2024